YU37301A - Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa - Google Patents
Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensaInfo
- Publication number
- YU37301A YU37301A YU37301A YU37301A YU37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pharmaceutical composition
- modified release
- insulin sensitiser
- antidiabetic agent
- another antidiabetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Farmaceutski preparat, koji sadrži: sensitizer insulina i drugi antidijabetski agens i farmaceutski prihvatljiv nosač, gde je preparat uredjen da obezbedi modifikovano oslobadjanje od bar jednog sensitizera insulina i drugog antidijabetskog agensa, i korišćenje takvog preparata u medicini.[A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824866.9A GB9824866D0 (en) | 1998-11-12 | 1998-11-12 | Novel composition and use |
GBGB9824867.7A GB9824867D0 (en) | 1998-11-12 | 1998-11-12 | Novel composition and use |
GBGB9824869.3A GB9824869D0 (en) | 1998-11-12 | 1998-11-12 | Novel composition and use |
GBGB9912193.1A GB9912193D0 (en) | 1999-05-25 | 1999-05-25 | Novel composition and use |
GBGB9912190.7A GB9912190D0 (en) | 1999-05-25 | 1999-05-25 | Novel composition and use |
GBGB9912191.5A GB9912191D0 (en) | 1999-05-25 | 1999-05-25 | Novel composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
YU37301A true YU37301A (sh) | 2005-06-10 |
Family
ID=27547326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU37301A YU37301A (sh) | 1998-11-12 | 1999-11-08 | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa |
Country Status (36)
Country | Link |
---|---|
EP (3) | EP1131070B1 (sh) |
JP (1) | JP2002529504A (sh) |
KR (1) | KR100643833B1 (sh) |
CN (1) | CN1230162C (sh) |
AR (1) | AR024228A1 (sh) |
AT (1) | ATE406889T1 (sh) |
AU (1) | AU768994B2 (sh) |
BG (2) | BG109852A (sh) |
BR (1) | BR9915285A (sh) |
CA (1) | CA2351058A1 (sh) |
CY (1) | CY1108587T1 (sh) |
CZ (1) | CZ20011629A3 (sh) |
DE (1) | DE69939485D1 (sh) |
DK (1) | DK1131070T3 (sh) |
DZ (1) | DZ2936A1 (sh) |
EA (2) | EA011633B1 (sh) |
ES (1) | ES2312221T3 (sh) |
HK (1) | HK1040910B (sh) |
HR (1) | HRP20010343B1 (sh) |
HU (1) | HUP0104303A3 (sh) |
ID (1) | ID28783A (sh) |
IL (2) | IL143002A0 (sh) |
MY (1) | MY124695A (sh) |
NO (1) | NO20012303L (sh) |
NZ (1) | NZ511614A (sh) |
OA (1) | OA11677A (sh) |
PE (1) | PE20001238A1 (sh) |
PL (1) | PL347634A1 (sh) |
PT (1) | PT1131070E (sh) |
SI (1) | SI1131070T1 (sh) |
SK (1) | SK287038B6 (sh) |
TR (1) | TR200101333T2 (sh) |
TW (2) | TWI251487B (sh) |
UY (1) | UY25799A1 (sh) |
WO (1) | WO2000028989A1 (sh) |
YU (1) | YU37301A (sh) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
AU777776B2 (en) | 1999-12-23 | 2004-10-28 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
AU2007201729B2 (en) * | 1999-12-23 | 2010-02-25 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
US6761901B1 (en) | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
FR2811227A1 (fr) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
US8257744B2 (en) * | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
EP1723948A1 (en) * | 2000-11-03 | 2006-11-22 | Andrx Labs, LLC | Controlled release compositions of biguanide with less side effects and treatment regimen thereof |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US6790459B1 (en) | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
FR2816840B1 (fr) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
EP1349531A1 (en) * | 2001-01-12 | 2003-10-08 | Sun Pharmaceuticals Industries Ltd. | Spaced drug delivery system |
US20030157166A1 (en) * | 2001-03-16 | 2003-08-21 | Chen Chih Ming | Controlled release sulfonylurea formulation |
FR2822069B1 (fr) * | 2001-03-19 | 2003-06-20 | Lipha | Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete |
AU2002314968B2 (en) * | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
EP1429740A4 (en) * | 2001-07-10 | 2005-01-26 | Kos Life Sciences Inc | CORE FORMULATION WITH TROGLITAZONE AND A BIGUANIDE |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
US7183321B2 (en) | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
EP1474108A2 (en) | 2002-01-09 | 2004-11-10 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
MY139719A (en) * | 2002-02-12 | 2009-10-30 | Glaxo Group Ltd | Oral dosage form for controlled drug release |
EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
EP1515701B1 (en) * | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
NZ541749A (en) | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
AR045330A1 (es) * | 2003-08-07 | 2005-10-26 | Sb Pharmco Inc | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla |
GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
HUE028576T2 (en) | 2003-10-31 | 2016-12-28 | Takeda Pharmaceuticals Co | Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
JP2007534704A (ja) * | 2004-04-29 | 2007-11-29 | 美時化学製薬股▲ふん▼有限公司 | 経口徐放性錠剤組成物およびその製造方法 |
CN1327840C (zh) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
KR100657785B1 (ko) * | 2005-02-19 | 2007-04-16 | 한국유나이티드제약 주식회사 | 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물 |
US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
MXPA05010977A (es) * | 2005-10-12 | 2007-04-11 | Abdala Leopoldo Espinosa | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
MXPA05014092A (es) * | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2. |
TWI384985B (zh) | 2005-12-22 | 2013-02-11 | Takeda Pharmaceutical | 固體製劑 |
WO2008026668A1 (fr) * | 2006-08-31 | 2008-03-06 | Daiichi Sankyo Company, Limited | Composition médicale contenant un agent d'amélioration de la résistance à l'insuline |
KR100812538B1 (ko) * | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | 약물 제어방출형 메트포르민-글리메피리드 복합제제 |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
AU2008223091B2 (en) * | 2007-03-02 | 2014-04-24 | Farnam Companies, Inc. | Sustained release pellets comprising wax-like material |
WO2009017383A2 (en) * | 2007-08-02 | 2009-02-05 | Handok Pharmaceuticals Co., Ltd. | Sustained-release formulation comprising metformin acid salt |
KR101552187B1 (ko) | 2007-09-10 | 2015-09-10 | 얀센 파마슈티카 엔.브이. | Sglt 억제제로서 유용한 화합물의 제조 방법 |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
CN101548961B (zh) * | 2008-04-03 | 2011-05-04 | 单宝华 | 一种治疗糖尿病及肥胖症的口服胶囊制剂 |
WO2010026467A2 (en) * | 2008-09-04 | 2010-03-11 | Torrent Pharmaceuticals Ltd. | Controlled release dosage form of high solubility active ingredient |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
KR101189639B1 (ko) * | 2008-12-15 | 2012-10-12 | 씨제이제일제당 (주) | 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법 |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
EA024368B1 (ru) | 2009-10-14 | 2016-09-30 | Янссен Фармацевтика Нв | Процесс получения соединений для применения в качестве ингибиторов sglt2 |
JP6227406B2 (ja) | 2010-05-11 | 2017-11-08 | ヤンセン ファーマシューティカ エヌ.ベー. | SGLTの阻害剤としての1−(β−D−グルコピラノシル)−2−チエニル−メチルベンゼン誘導体を含有する医薬製剤 |
US20120009259A1 (en) * | 2010-07-06 | 2012-01-12 | Urbain Alfons Clementina Delaet | Formulation for co-therapy treatment of diabetes |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
MX2013007884A (es) | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
CA2832938C (en) | 2011-04-13 | 2019-09-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
CN110693867A (zh) * | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
CN102631332A (zh) * | 2012-04-28 | 2012-08-15 | 邹立兴 | 一种伏格列波糖片剂及其制备方法 |
KR101409330B1 (ko) * | 2012-05-11 | 2014-06-18 | 안국약품 주식회사 | 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법 |
WO2014128116A1 (en) * | 2013-02-19 | 2014-08-28 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A production process for gliclazide formulations |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
CN105963280B (zh) * | 2016-06-30 | 2018-11-06 | 合肥华方医药科技有限公司 | 一种伏格列波糖口腔速溶膜及其制备方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
US4538469A (en) * | 1983-07-29 | 1985-09-03 | Panametrics, Inc. | Integrated threshold arming method and apparatus |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
DK173350B1 (da) | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
JPH06779B2 (ja) | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
ES2137915T3 (es) | 1987-09-04 | 2000-01-01 | Beecham Group Plc | Derivados de tiazolidindiona sustituida. |
US4791125A (en) | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
US5061717A (en) | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
MX15171A (es) | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
JP2630016B2 (ja) * | 1990-05-21 | 1997-07-16 | ヤマハ株式会社 | 吹奏感付加器を有する電子管楽器 |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
PL296945A1 (sh) | 1990-07-03 | 1992-07-13 | Yamanouchi Pharma Co Ltd | |
KR930701420A (ko) | 1990-08-23 | 1993-06-11 | 알렌 제이. 스피겔 | 혈당저하제로서의 하이드록시우레아 유도체 |
JPH04210683A (ja) | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5183823A (en) | 1991-04-11 | 1993-02-02 | Takeda Chemical Industries, Ltd. | Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents |
SK109993A3 (en) | 1991-04-11 | 1994-12-07 | Upjohn Co | Thiazolidinedione derivatives producing and use thereof |
US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
TW222626B (sh) | 1991-07-22 | 1994-04-21 | Pfizer | |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH05271204A (ja) | 1992-03-26 | 1993-10-19 | Japan Tobacco Inc | 新規なトリアジン誘導体 |
US5264451A (en) | 1992-04-07 | 1993-11-23 | American Home Products Corporation | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones |
JPH07505647A (ja) | 1992-04-10 | 1995-06-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 複素環化合物および2型糖尿病の治療におけるそれらの使用 |
AU4104593A (en) | 1992-05-05 | 1993-11-29 | Upjohn Company, The | A process for producing pioglitazone metabolite |
CA2139442A1 (en) | 1992-07-03 | 1994-01-20 | David Haigh | Heterocyclic compounds as pharmaceutical |
US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
RU2071783C1 (ru) * | 1993-09-07 | 1997-01-20 | Ессентукский центральный военный санаторий | Способ получения средства для лечения сахарного диабета |
US5457109A (en) | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
RU2114617C1 (ru) * | 1996-09-27 | 1998-07-10 | Юрий Георгиевич Каминский | Антидиабетическое средство на основе янтарной кислоты |
IL132032A0 (en) * | 1997-03-24 | 2001-03-19 | Galderma Res & Dev | Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus |
GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
-
1999
- 1999-11-08 BR BR9915285-1A patent/BR9915285A/pt not_active Application Discontinuation
- 1999-11-08 IL IL14300299A patent/IL143002A0/xx unknown
- 1999-11-08 YU YU37301A patent/YU37301A/sh unknown
- 1999-11-08 DK DK99964483T patent/DK1131070T3/da active
- 1999-11-08 PL PL99347634A patent/PL347634A1/xx not_active Application Discontinuation
- 1999-11-08 OA OA1200100117A patent/OA11677A/en unknown
- 1999-11-08 EA EA200601145A patent/EA011633B1/ru not_active IP Right Cessation
- 1999-11-08 EP EP99964483A patent/EP1131070B1/en not_active Revoked
- 1999-11-08 KR KR1020017005967A patent/KR100643833B1/ko not_active IP Right Cessation
- 1999-11-08 CA CA002351058A patent/CA2351058A1/en not_active Abandoned
- 1999-11-08 SI SI9931017T patent/SI1131070T1/sl unknown
- 1999-11-08 EP EP07105992A patent/EP1813273A1/en not_active Withdrawn
- 1999-11-08 NZ NZ511614A patent/NZ511614A/en not_active IP Right Cessation
- 1999-11-08 TR TR2001/01333T patent/TR200101333T2/xx unknown
- 1999-11-08 WO PCT/EP1999/008704 patent/WO2000028989A1/en active IP Right Grant
- 1999-11-08 HU HU0104303A patent/HUP0104303A3/hu unknown
- 1999-11-08 JP JP2000582036A patent/JP2002529504A/ja not_active Ceased
- 1999-11-08 EA EA200100541A patent/EA007610B1/ru not_active IP Right Cessation
- 1999-11-08 CN CNB998154792A patent/CN1230162C/zh not_active Expired - Fee Related
- 1999-11-08 DE DE69939485T patent/DE69939485D1/de not_active Expired - Lifetime
- 1999-11-08 CZ CZ20011629A patent/CZ20011629A3/cs unknown
- 1999-11-08 PT PT99964483T patent/PT1131070E/pt unknown
- 1999-11-08 AU AU30338/00A patent/AU768994B2/en not_active Ceased
- 1999-11-08 EP EP08163249A patent/EP1992337A1/en not_active Withdrawn
- 1999-11-08 ID IDW00200101045A patent/ID28783A/id unknown
- 1999-11-08 AT AT99964483T patent/ATE406889T1/de active
- 1999-11-08 SK SK644-2001A patent/SK287038B6/sk not_active IP Right Cessation
- 1999-11-08 ES ES99964483T patent/ES2312221T3/es not_active Expired - Lifetime
- 1999-11-10 AR ARP990105697A patent/AR024228A1/es unknown
- 1999-11-10 DZ DZ990236A patent/DZ2936A1/xx active
- 1999-11-11 MY MYPI99004896A patent/MY124695A/en unknown
- 1999-11-12 UY UY25799A patent/UY25799A1/es not_active Application Discontinuation
- 1999-11-12 PE PE1999001146A patent/PE20001238A1/es not_active Application Discontinuation
- 1999-12-24 TW TW093109152A patent/TWI251487B/zh not_active IP Right Cessation
- 1999-12-24 TW TW088122853A patent/TW592694B/zh not_active IP Right Cessation
-
2001
- 2001-05-07 IL IL143002A patent/IL143002A/en not_active IP Right Cessation
- 2001-05-10 NO NO20012303A patent/NO20012303L/no not_active Application Discontinuation
- 2001-05-11 HR HR20010343A patent/HRP20010343B1/xx not_active IP Right Cessation
- 2001-06-07 BG BG109852A patent/BG109852A/bg unknown
- 2001-06-07 BG BG105568A patent/BG65351B1/bg unknown
-
2002
- 2002-02-08 HK HK02101023.7A patent/HK1040910B/zh not_active IP Right Cessation
-
2008
- 2008-11-24 CY CY20081101346T patent/CY1108587T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
MY129356A (en) | Electrospun pharmaceutical compositions | |
MY125516A (en) | Novel composition based on thiazolidinedione and metformin and use | |
PL357944A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
MXPA02012763A (es) | Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus. | |
TW355683B (en) | Composition containing micronized nebivolol | |
WO2002018327A3 (en) | Guanidinobenzamides as mc4-r agonists | |
HRP20080117A2 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
AU2002231691A1 (en) | Novel medicament compositions based on anticholinesterase drugs and on ciclesonides | |
AU2084801A (en) | Antiviral medication | |
HK1045113A1 (zh) | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 | |
FR2735369B1 (fr) | Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside | |
WO2002053090A3 (fr) | Association medicamenteuse d'une biguanine (metformine) et d'arginine | |
GB9816899D0 (en) | Therapeutic agents | |
MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
AR019724A2 (es) | Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas | |
AR008025A1 (es) | Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina | |
AP1692A (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. | |
IL131267A0 (en) | A medicament against infertility and for increasing fertility | |
JP2002500181A5 (sh) | ||
AU2502301A (en) | Medicament and combination of compatible medicaments | |
AU7370798A (en) | Compositions and methods of therapy for igf-i-responsive conditions | |
ECSP993215A (es) | Nueva composicion y uso | |
UA38697A (uk) | Спосіб лікування генералізованого пародонтиту | |
ECSP993216A (es) | Nueva composicion y uso ii |